Antiviral therapy
AssigneesUniversiteit Utrecht, Universitair Medisch Centrum Utrecht
InventorJohannes Servatius Leonardus Maria Nottet
Life of this patent
Estimating the term…
Abstract
The invention relates to the field of antiviral agents, and more specifically to antiviral therapy. The invention provides use of at least one compound or mixture of compounds of the general formula 1 or a functional equivalent or pharmaceutically acceptable salt or hydrate thereof for the production of a pharmaceutical composition for the treatment of a viral infection.
Claims20
A method for treating a viral infection in a subject suffering therefrom with a first antiviral agent, the viral infection caused by a virus at least partially resistant to a second antiviral agent, said method comprising:
- administering to the subject the first antiviral agent wherein said first antiviral agent comprises a compound of the general formula
- 6
- wherein X and Y are independently selected from the group consisting of O, S, SO, SO2, and SO3;
- wherein n is 0, 1, 2, 3, 4;
- wherein R, R′ are independently H with the proviso that when R is H, R′ is not H, a C1-C10, branched or unbranched, substituted or unsubstituted (preferably the substitute is one or more of halogen or CF3), saturated or (poly)unsaturated, (cyclo)alkyl, alkene, alkyn, (cyclo)aryl, aryl(cyclo)alkyl, (cyclo)alkylaryl, alkoxyaryl, alkoxyalkene, alkoxyalkyne, enyne, diene, diyne or alkoxyalkyl, preferably selected from the group consisting of H, CH3, CF3, CH2Cl, CH2Br, CH2CH3, (CH2)2CH3, (CH2)3CH3, (CH2)4CH3, (CH2)5CH3, (CH2)6CH3, CH(CH3)2, CH(CH3)3, CH═C═CH2, (CH2)2O(CH2)3CH3, CH2HC═CH(CH2)3CH3, CH2C═C(CH2)3CH3, CH2C═C(CH2)2CH3, CH2C═C—CCH2CH3, CH2C═C—CH3 and CH2C═CH and isomers or homologues thereof;
- and
- Z is independently R, R′, XR, XR′, YR or YR′ or a functional equivalent thereof.
A method of treating a viral infection in a subject suffering therefrom with a first antiviral agent, said viral infection caused by a virus that is at least partly resistant to a second antiviral agent, said method comprising administering to the subject said first antiviral agent wherein said first antiviral agent comprises a compound of the general formula
- 7
- or a functional equivalent thereof, wherein R is selected from the group consisting of H, CH3, CH2CH3, (CH2)2CH3, (CH2)3CH3, (CH2)4CH3, (CH2)5CH3, (CH2)6CH3, CH(CH3)2, CH(CH33, CH═C═CH2, (CH2)2O(CH2)3CH3, CH2HC═CH(CH2)3CH3, CH2C═C(CH2)3CH3, CCH2C═C(CH2)2CH3, CH2C═C—CCH2CH3, CH2C═C—CH3 and CH2C═CH and isomers or homologues thereof, and R′ is selected from the group consisting of H, CH3, CF3, CH2CL and CH2Br.
A pharmaceutical composition for the treatment of a viral infection comprising a compound a first antiviral agent or a pharmaceutically acceptable salt or hydrate thereof, said first antiviral agent comprising a compound of the general formula
- 8
- wherein X and Y are independently selected from the group consisting of O, S, SO, SO2, and SO3;
- wherein n is 0, 1, 2, 3, 4;
- wherein R, R′ are independently H with the proviso that when R is H, R′ is not H, a C1-C10, branched or unbranched, substituted or unsubstituted (preferably the substitute is one or more of halogen or CF3), saturated or (poly)unsaturated, (cyclo)alkyl, alkene, alkyn, (cyclo)aryl, aryl(cyclo)alkyl, (cyclo)alkylaryl, alkoxyaryl, alkoxyalkene, alkoxyalkyne, enyne, diene, diyne or alkoxyalkyl, preferably selected from the group consisting of H, CH3, CF3, CH2Cl, CH2Br, CH2CH3, (CH2)2CH3, (CH2)3CH3, (CH2)4CH3, (CH2)5CH3, (CH2)6CH3, CH(CH3)2, CH(CH3)3, CH═C═CH2, (CH2)2O(CH2)3CH3, CH2HC═CH(CH2)3CH3, CH2C═C(CH2)3CH3, CH2C═C(CH2)2CH3, CH2C═C—CCH2CH3, CH2C═C—CH3 and CH2C═CH and isomers or homologues thereof;
- and Z is independently selected from the group consisting of R, R′, XR, XR′, YR and YR′ or a functional equivalent thereof.
Dependencies are inferred from the claim text.